163 related articles for article (PubMed ID: 36436128)
41. Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65.
O'Neill SC; Isaacs C; Lynce F; Graham DM; Chao C; Sheppard VB; Zhou Y; Liu C; Selvam N; Schwartz MD; Potosky AL
Breast Cancer Res; 2017 Mar; 19(1):45. PubMed ID: 28359319
[TBL] [Abstract][Full Text] [Related]
42. Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer.
Reeder-Hayes KE; Meyer AM; Dusetzina SB; Liu H; Wheeler SB
Breast Cancer Res Treat; 2014 Jun; 145(3):743-51. PubMed ID: 24789443
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
Lee C; Check DK; Manace Brenman L; Kushi LH; Epstein MM; Neslund-Dudas C; Pawloski PA; Achacoso N; Laurent C; Fehrenbacher L; Habel LA
Breast Cancer Res Treat; 2020 Feb; 180(1):219-226. PubMed ID: 31975315
[TBL] [Abstract][Full Text] [Related]
44. Initiation of Adjuvant Endocrine Therapy in Black and White Women With Breast Cancer.
Sheppard VB; de Mendoza AH; He J; Jennings Y; Edmonds MC; Oppong BA; Tadesse MG
Clin Breast Cancer; 2018 Oct; 18(5):337-346.e1. PubMed ID: 29422259
[TBL] [Abstract][Full Text] [Related]
45. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
[TBL] [Abstract][Full Text] [Related]
46. Adjuvant therapy use among Appalachian breast cancer survivors.
Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
[TBL] [Abstract][Full Text] [Related]
47. Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?
Seneviratne S; Campbell I; Scott N; Kuper-Hommel M; Kim B; Pillai A; Lawrenson R
Breast; 2015 Feb; 24(1):62-7. PubMed ID: 25486877
[TBL] [Abstract][Full Text] [Related]
48. Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer.
Cho B; Pérez M; Jeffe DB; Kreuter MW; Margenthaler JA; Colditz GA; Liu Y
BMC Cancer; 2022 Aug; 22(1):837. PubMed ID: 35915419
[TBL] [Abstract][Full Text] [Related]
49. Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL).
Neugut AI; Hillyer GC; Kushi LH; Lamerato L; Leoce N; Nathanson SD; Ambrosone CB; Bovbjerg DH; Mandelblatt JS; Magai C; Tsai WY; Jacobson JS; Hershman DL
Breast Cancer Res Treat; 2012 Jul; 134(1):419-28. PubMed ID: 22527111
[TBL] [Abstract][Full Text] [Related]
50. Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.
Partridge AH; Niman SM; Ruggeri M; Peccatori FA; Azim HA; Colleoni M; Saura C; Shimizu C; Sætersdal AB; Kroep JR; Mailliez A; Warner E; Borges VF; Amant F; Gombos A; Kataoka A; Rousset-Jablonski C; Borstnar S; Takei J; Lee JE; Walshe JM; Borrego MR; Moore HC; Saunders C; Cardoso F; Susnjar S; Bjelic-Radisic V; Smith KL; Piccart M; Korde LA; Goldhirsch A; Gelber RD; Pagani O
Breast; 2021 Oct; 59():327-338. PubMed ID: 34390999
[TBL] [Abstract][Full Text] [Related]
51. A mixed-methods study of the technical feasibility and patient acceptability of a real-time adherence monitor in breast cancer survivors taking adjuvant endocrine therapy.
Bright EE; Genung SR; Stanton AL; Arch JJ
Breast Cancer Res Treat; 2022 Oct; 195(3):393-399. PubMed ID: 35962148
[TBL] [Abstract][Full Text] [Related]
52. Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.
Bowles EJA; Ramin C; Buist DSM; Feigelson HS; Weinmann S; Veiga LHS; Bodelon C; Curtis RE; Vo JB; Berrington de Gonzalez A; Gierach GL
Breast Cancer Res Treat; 2022 May; 193(1):203-216. PubMed ID: 35275285
[TBL] [Abstract][Full Text] [Related]
53. Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.
Wulaningsih W; Garmo H; Ahlgren J; Holmberg L; Folkvaljon Y; Wigertz A; Van Hemelrijck M; Lambe M
Breast Cancer Res Treat; 2018 Nov; 172(1):167-177. PubMed ID: 30030708
[TBL] [Abstract][Full Text] [Related]
54. Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study.
Harborg S; Heide-Jørgensen U; Ahern TP; Ewertz M; Cronin-Fenton D; Borgquist S
Breast Cancer Res Treat; 2020 Aug; 183(1):153-160. PubMed ID: 32572715
[TBL] [Abstract][Full Text] [Related]
55. Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.
van Hellemond IEG; Geurts SME; Tjan-Heijnen VCG
Curr Treat Options Oncol; 2018 Apr; 19(5):26. PubMed ID: 29704066
[TBL] [Abstract][Full Text] [Related]
56. Information for decision making by post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy.
Feldman-Stewart D; Madarnas Y; Mates M; Tong C; Grunfeld E; Verma S; Carolan H; Brundage M
Breast; 2013 Oct; 22(5):919-25. PubMed ID: 23721853
[TBL] [Abstract][Full Text] [Related]
57. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
58. Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.
Farias AJ; Du XL
Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1266-1275. PubMed ID: 28515111
[No Abstract] [Full Text] [Related]
59. Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer.
Sood N; Liu Y; Lian M; Greever-Rice T; Lucht J; Schmaltz C; Colditz GA
JAMA Netw Open; 2022 Aug; 5(8):e2225345. PubMed ID: 35921108
[TBL] [Abstract][Full Text] [Related]
60. Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer.
Corter AL; Broom R; Porter D; Harvey V; Findlay M
Psychooncology; 2018 Sep; 27(9):2096-2103. PubMed ID: 29776011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
